Neutropenia in Allogeneic Marrow Transplant Recipients Receiving Ganciclovir for Prevention of Cytomegalovirus Disease: Risk Factors and Outcome
Open Access
- 15 September 1997
- journal article
- Published by American Society of Hematology in Blood
- Vol. 90 (6) , 2502-2508
- https://doi.org/10.1182/blood.v90.6.2502
Abstract
To determine risk factors, frequency, time patterns, and outcome of ganciclovir-related neutropenia in allogeneic marrow transplant recipients, 278 consecutive patients receiving ganciclovir from engraftment until day 100 were studied. In this cohort, 159 patients (57%) had absolute neutrophil counts (ANC) less than 1,500/μL, 112 (41%) had an ANC less than 1,000/μL, 87 (31%) less than 750/μL, and 56 (21%) less than 500/μL for at least 2 consecutive days. Statistically significant risk factors for neutropenia in a Cox model were low marrow cellularity between day 21 and 28 (relative risk [RR] 2.4, P = .0002), hyperbilirubinemia ≥6 mg/dL during the first 20 days (RR 2.5, P = .0001), and elevation of serum creatinine ≥2 mg/dL after day 21 after transplant (RR 2.1, P = .001). Restriction to factors present at engraftment resulted in a similar model with low marrow cellularity, hyperbilirubinemia ≥6 mg/dL, and elevated serum creatinine as significant risk factors. Patients with no risk factor had an incidence of neutropenia of 21%, an incidence of 31% for one risk factor, and of 57% for two or more risk factors (RR 3.8, P = .001). Neutropenia was a negative predictor of overall (RR 2.0, P = .0001) and event-free survival (RR 2.1, P < .0001), and a predictor of relapse (RR 1.7, P = .03) and nonrelapse mortality (RR 2.1, P = .003). Thus, early liver dysfunction, elevated serum creatinine, and low marrow cellularity are risk factors for ganciclovir-related neutropenia. Neutropenia in ganciclovir recipients after marrow transplantation is an independent risk factor for mortality.Keywords
This publication has 25 references indexed in Scilit:
- Phase I Study of Amphotericin B Colloidal Dispersion for the Treatment of Invasive Fungal Infections after Marrow TransplantThe Journal of Infectious Diseases, 1996
- Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modellingAntimicrobial Agents and Chemotherapy, 1995
- Morbidity and Toxic Effects Associated With Ganciclovir or Foscarnet Therapy in a Randomized Cytomegalovirus Retinitis TrialArchives of internal medicine (1960), 1995
- Summarizing data on survival, relapse, and chronic graft‐versus‐host disease after bone marrow transplantation: motivation for and description of new methodsBritish Journal of Haematology, 1993
- A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart TransplantationNew England Journal of Medicine, 1992
- Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1991
- Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infectionBritish Journal of Haematology, 1991
- A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow TransplantsNew England Journal of Medicine, 1991
- Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitroAntimicrobial Agents and Chemotherapy, 1987
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976